Biosimulation Market by Offering, Application, Indication, End User, & Region -Global Forecast to 2029

TABLE OF CONTENTS

1 INTRODUCTION

• 1.1 STUDY OBJECTIVES
• 1.2 MARKET DEFINITION
• 1.3 STUDY SCOPE
  • 1.3.1 MARKETS COVERED & REGIONAL SCOPE
  • 1.3.2 INCLUSIONS & EXCLUSIONS
  • 1.3.3 YEARS CONSIDERED
• 1.4 CURRENCY CONSIDERED
• 1.5 STAKEHOLDERS
• 1.6 SUMMARY OF CHANGES

2 RESEARCH METHODOLOGY

• 2.1 RESEARCH DATA
  • 2.1.1 SECONDARY DATA
    • 2.1.1.1 Key data from secondary sources
  • 2.1.2 PRIMARY DATA
    • 2.1.2.1 Key data from primary sources
    • 2.1.2.2 Insights from primary experts
• 2.2 MARKET SIZE ESTIMATION
• 2.3 DATA TRIANGULATION
• 2.4 MARKET SHARE ESTIMATION
• 2.5 RESEARCH ASSUMPTIONS
• 2.6 LIMITATIONS
  • 2.6.1 METHODOLOGY-RELATED LIMITATIONS
  • 2.6.2 SCOPE-RELATED LIMITATIONS
• 2.7 RISK ASSESSMENT

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

• 4.1 BIOSIMULATION MARKET OVERVIEW
• 4.2 ASIA PACIFIC: BIOSIMULATION MARKET, BY REVENUE MODEL AND COUNTRY (2023)
• 4.3 BIOSIMULATION MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
• 4.4 BIOSIMULATION MARKET: REGIONAL MIX (2024-2029)
• 4.5 BIOSIMULATION MARKET: DEVELOPED VS. EMERGING ECONOMIES

5 MARKET OVERVIEW

• 5.1 INTRODUCTION
• 5.2 MARKET DYNAMICS
  • 5.2.1 DRIVERS
    • 5.2.1.1 Increasing R&D investments in pharmaceutical and biotechnology industries
    • 5.2.1.2 Growing adoption of biosimulation software by regulatory bodies
    • 5.2.1.3 Integration of technologically advanced Quantitative Systems Pharmacology (QSP)
    • 5.2.1.4 Need to curtail drug discovery and development costs
    • 5.2.1.5 Growth in biologics and biosimilars markets
  • 5.2.2 RESTRAINTS
    • 5.2.2.1 Lack of standardization
    • 5.2.2.2 Data availability and quality
  • 5.2.3 OPPORTUNITIES
    • 5.2.3.1 Emerging applications
    • 5.2.3.2 Use of biosimulation solutions for pediatric drug development
  • 5.2.4 CHALLENGES
    • 5.2.4.1 Difficulties in matching complexity of biological systems and processes
    • 5.2.4.2 Shortage of biosimulation and modeling experts
• 5.3 ECOSYSTEM ANALYSIS
  • 5.3.1 SOFTWARE PROVIDERS
  • 5.3.2 PHARMACEUTICAL & BIOTECH COMPANIES
  • 5.3.3 CONTRACT RESEARCH ORGANIZATIONS (CROS)
  • 5.3.4 REGULATORY BODIES
  • 5.3.5 ACADEMIC & RESEARCH INSTITUTIONS
• 5.4 CASE STUDY ANALYSIS
  • 5.4.1 CASE STUDY 1: OPTIMIZING ASCIMINIB DEVELOPMENT THROUGH ADVANCED PBPK MODELING
  • 5.4.2 CASE STUDY 2: COMPUTATIONAL DISCOVERY OF SELECTIVE WEE1 INHIBITORS FOR CANCER
  • 5.4.3 CASE STUDY 3: EFFICIENT CLINICAL TRIAL UTILIZING SCALE MANAGEMENT EXPERTISE
• 5.5 VALUE CHAIN ANALYSIS
• 5.6 PORTER'S FIVE FORCES ANALYSIS
  • 5.6.1 BARGAINING POWER OF SUPPLIERS
  • 5.6.2 BARGAINING POWER OF BUYERS
  • 5.6.3 THREAT OF SUBSTITUTES
  • 5.6.4 THREAT OF NEW ENTRANTS
  • 5.6.5 INTENSITY OF COMPETITIVE RIVALRY
• 5.7 REGULATORY ANALYSIS
  • 5.7.1 REGULATORY LANDSCAPE
    • 5.7.1.1 North America
    • 5.7.1.2 Europe
    • 5.7.1.3 Asia Pacific
    • 5.7.1.4 Latin America
    • 5.7.1.5 Middle East & Africa
  • 5.7.2 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
• 5.8 PATENT ANALYSIS
  • 5.8.1 PATENT PUBLICATION TRENDS FOR BIOSIMULATION
  • 5.8.2 JURISDICTION AND TOP APPLICANT ANALYSIS
• 5.9 TECHNOLOGY ANALYSIS
  • 5.9.1 KEY TECHNOLOGIES
    • 5.9.1.1 Mathematical modeling
    • 5.9.1.2 Software platforms
    • 5.9.1.3 Quantitative systems pharmacology (QSP)
  • 5.9.2 COMPLEMENTARY TECHNOLOGIES
    • 5.9.2.1 Data analytics
    • 5.9.2.2 Machine learning and AI
  • 5.9.3 ADJACENT TECHNOLOGIES
    • 5.9.3.1 In silico trials
• 5.10 INDUSTRY TRENDS
  • 5.10.1 DISCOVERY OF BIOMARKERS
  • 5.10.2 ADOPTION IN PERSONALIZED MEDICINE
• 5.11 PRICING ANALYSIS
  • 5.11.1 INDICATIVE PRICING ANALYSIS OF KEY PLAYERS, BY OFFERING, 2023
  • 5.11.2 AVERAGE SELLING PRICE TREND, BY REGION (QUALITATIVE)
• 5.12 KEY CONFERENCES & EVENTS, 2024-2025
• 5.13 KEY STAKEHOLDERS & BUYING CRITERIA
  • 5.13.1 BUYING CRITERIA
• 5.14 TRENDS & DISRUPTIONS IMPACTING CUSTOMERS' BUSINESSES
• 5.15 END-USER ANALYSIS
  • 5.15.1 UNMET NEEDS
  • 5.15.2 END-USER EXPECTATIONS
• 5.16 INVESTMENT & FUNDING SCENARIO
• 5.17 IMPACT OF AI/GEN AI ON BIOSIMULATION MARKET
  • 5.17.1 KEY USE CASES
  • 5.17.2 IMPACT OF AI/GEN AI ON INTERCONNECTED AND ADJACENT ECOSYSTEMS
    • 5.17.2.1 Case study
    • 5.17.2.2 Bioinformatics market
    • 5.17.2.3 Drug discovery services market
    • 5.17.2.4 Drug discovery informatics market
  • 5.17.3 USER READINESS & IMPACT ASSESSMENT
    • 5.17.3.1 User readiness
      • 5.17.3.1.1 Pharmaceutical & biotechnology companies
      • 5.17.3.1.2 Contract research organizations
    • 5.17.3.2 Impact assessment
      • 5.17.3.2.1 User A: Pharmaceutical & biotechnology companies
        • 5.17.3.2.1.1 Implementation
        • 5.17.3.2.1.2 Impact
      • 5.17.3.2.2 User B: Academic & research institutes
        • 5.17.3.2.2.1 Implementation
        • 5.17.3.2.2.2 Impact

6 BIOSIMULATION MARKET, BY OFFERING

• 6.1 INTRODUCTION
• 6.2 SOFTWARE
  • 6.2.1 STANDALONE MODULES
    • 6.2.1.1 Molecular modeling & simulation software
      • 6.2.1.1.1 Growing importance of molecular modeling & simulation in drug discovery and development to accelerate market growth
    • 6.2.1.2 PK/PD modeling & simulation software
      • 6.2.1.2.1 Pivotal role in early drug development phase to boost market growth
    • 6.2.1.3 PBPK modeling & simulation software
      • 6.2.1.3.1 Widespread use by regulatory bodies to drive PBPK modeling & simulation software market
    • 6.2.1.4 Toxicity prediction software
      • 6.2.1.4.1 Pressing need for toxicity prediction in drug discovery and development is driving the market
    • 6.2.1.5 Clinical trial simulation software
      • 6.2.1.5.1 High failure rate of clinical trials to accelerate growth
    • 6.2.1.6 Other biosimulation software
  • 6.2.2 INTEGRATED SOFTWARE SUITES/PLATFORMS
    • 6.2.2.1 Need for efficient R&D tools to accelerate growth of integrated platforms
• 6.3 SERVICES
  • 6.3.1 CONSULTING & ADVISORY
    • 6.3.1.1 Need to focus on core competencies to drive need for consulting & advisory services
  • 6.3.2 IMPLEMENTATION, TRAINING, AND SUPPORT
    • 6.3.2.1 Need for well-trained professionals and experts to accelerate market growth
  • 6.3.3 DATA ANALYSIS & INTERPRETATION
    • 6.3.3.1 Accurate and precise interpretation of data to drive need for data analysis & interpretation services

7 BIOSIMULATION MARKET, BY APPLICATION

• 7.1 INTRODUCTION
• 7.2 DRUG DISCOVERY
  • 7.2.1 TARGET IDENTIFICATION & VALIDATION
    • 7.2.1.1 Need for identification of optimal targets in drug discovery to drive market
  • 7.2.2 LEAD IDENTIFICATION & OPTIMIZATION
    • 7.2.2.1 Crucial role in facilitating viable drug discovery to accelerate market growth
• 7.3 DRUG DEVELOPMENT
  • 7.3.1 PRECLINICAL TESTING
    • 7.3.1.1 PK/PD
      • 7.3.1.1.1 Critical role of PK/PD studies in drug development to drive market
    • 7.3.1.2 ADME/Toxicology
      • 7.3.1.2.1 Growing role in selection of potent drug molecules to boost market growth
  • 7.3.2 CLINICAL TRIALS
    • 7.3.2.1 Phase I
      • 7.3.2.1.1 Growing need to ease decision-making process to drive segmental growth
    • 7.3.2.2 Phase II
      • 7.3.2.2.1 Efficiency in dose assessment and product efficacy to drive growth
    • 7.3.2.3 Phase III
      • 7.3.2.3.1 Need to curtail large costs involved in trials to propel demand
    • 7.3.2.4 Phase IV/Post-marketing surveillance
      • 7.3.2.4.1 Ability to assist researchers in process innovation and decision support to drive adoption
• 7.4 DISEASE MODELING
  • 7.4.1 CAPABILITY TO PREDICT DISEASE DYNAMICS AND INFORM THERAPEUTIC STRATEGIES TO DRIVE MARKET GROWTH
• 7.5 MANUFACTURING & SUPPLY CHAIN MANAGEMENT
  • 7.5.1 PRODUCTION PLANNING & OPTIMIZATION
    • 7.5.1.1 Need for proper production planning and execution to drive market growth
  • 7.5.2 QUALITY CONTROL & PROCESS MONITORING
    • 7.5.2.1 Adherence to maintaining product quality to fuel market growth
  • 7.5.3 DEMAND FORECASTING & INVENTORY MANAGEMENT
    • 7.5.3.1 Need to forecast demand effectively to drive market growth
  • 7.5.4 RISK MANAGEMENT & CONTINGENCY PLANNING
    • 7.5.4.1 Need to maintain operational continuity to support market growth
  • 7.5.5 OTHER MANUFACTURING & SUPPLY CHAIN MANAGEMENT APPLICATIONS
• 7.6 OTHER APPLICATIONS

8 BIOSIMULATION MARKET, BY THERAPEUTIC AREA

• 8.1 INTRODUCTION
• 8.2 ONCOLOGY
  • 8.2.1 HIGH PREVALENCE OF CANCER AND SHORTAGE OF EFFECTIVE CANCER DRUGS TO DRIVE MARKET GROWTH
• 8.3 CARDIOVASCULAR DISEASES
  • 8.3.1 RISING NEED FOR DRUGS TO TREAT CARDIOVASCULAR DISEASES TO BOOST MARKET
• 8.4 NEUROLOGICAL DISORDERS
  • 8.4.1 NEED TO BOOST DRUG DISCOVERY AND DEVELOPMENT FOR NEUROLOGICAL DISORDERS TO SUPPORT MARKET GROWTH
• 8.5 INFECTIOUS DISEASES
  • 8.5.1 RISING EPIDEMIC OUTBREAKS TO BOOST DRUG DISCOVERY ACTIVITY
• 8.6 OTHER THERAPEUTIC AREAS

9 BIOSIMULATION MARKET, BY REVENUE MODEL

• 9.1 INTRODUCTION
• 9.2 LICENSE-BASED MODELS
  • 9.2.1 LICENSE-BASED MODELS TO ACCOUNT FOR LARGEST SHARE OF MARKET
• 9.3 SUBSCRIPTION-BASED MODELS
  • 9.3.1 SUBSCRIPTION-BASED MODELS TO REGISTER HIGHEST GROWTH RATE DURING FORECAST PERIOD
• 9.4 SERVICE-BASED MODELS
  • 9.4.1 SPECIALIZED SIMULATION EXPERTISE WITH SERVICE-BASED MODELS TO SUPPORT ADOPTION
• 9.5 PAY-PER-USE MODELS
  • 9.5.1 RISING DEMAND FOR FLEXIBLE BIOSIMULATION SOLUTIONS WITHOUT UPFRONT COSTS TO SUPPORT MARKET GROWTH

10 BIOSIMULATION MARKET, BY DEPLOYMENT MODEL

• 10.1 INTRODUCTION
• 10.2 ON-PREMISE MODELS
  • 10.2.1 OPTIMAL CONTROL ON DEPLOYMENT AND DATA BACKUP TO SUPPORT MARKET UPTAKE
• 10.3 CLOUD-BASED MODELS
  • 10.3.1 CLOUD-BASED MODEL TO EXPERIENCE HIGHEST GROWTH RATE DURING FORECAST PERIOD
• 10.4 HYBRID MODELS
  • 10.4.1 BALANCED CAPABILITIES OF HYBRID BIOSIMULATION MODELS TO ACCELERATE ADOPTION

11 BIOSIMULATION MARKET, BY END USER

• 11.1 INTRODUCTION
• 11.2 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES
  • 11.2.1 INCREASING R&D EXPENDITURE FOR DRUG DISCOVERY AND DEVELOPMENT TO DRIVE MARKET
• 11.3 CONTRACT RESEARCH ORGANIZATIONS
  • 11.3.1 RISING OUTSOURCING OF CLINICAL TRIAL ACTIVITIES TO CROS BY PHARMACEUTICAL COMPANIES TO DRIVE MARKET
• 11.4 ACADEMIC & RESEARCH INSTITUTES
  • 11.4.1 FAVORABLE GOVERNMENT SUPPORT FOR RESEARCH TO SUPPORT MARKET GROWTH
• 11.5 REGULATORY BODIES
  • 11.5.1 GROWING USAGE OF BIOSIMULATION SOFTWARE FOR CLINICAL TRIAL EFFICACY TO PROPEL MARKET GROWTH
• 11.6 OTHER END USERS

12 BIOSIMULATION MARKET, BY REGION

• 12.1 INTRODUCTION
• 12.2 NORTH AMERICA
  • 12.2.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA
  • 12.2.2 US
    • 12.2.2.1 Rising government funding for pharmaceutical R&D to drive market
  • 12.2.3 CANADA
    • 12.2.3.1 Increasing funding by Canadian government in healthcare to drive market
• 12.3 EUROPE
  • 12.3.1 MACROECONOMIC OUTLOOK FOR EUROPE
  • 12.3.2 GERMANY
    • 12.3.2.1 High number of sponsored clinical trials to drive uptake of biosimulation
  • 12.3.3 UK
    • 12.3.3.1 Investments by pharmaceutical sponsors for drug discovery services to boost market
  • 12.3.4 FRANCE
    • 12.3.4.1 Growing R&D pipeline for clinical trials to drive market
  • 12.3.5 ITALY
    • 12.3.5.1 Increasing government funds and favorable regulatory scenarios to fuel uptake
  • 12.3.6 SPAIN
    • 12.3.6.1 Established network of research centers to propel market
  • 12.3.7 REST OF EUROPE
• 12.4 ASIA PACIFIC
  • 12.4.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC
  • 12.4.2 CHINA
    • 12.4.2.1 Low cost of drug development and large pharmaceutical R&D base to drive market
  • 12.4.3 INDIA
    • 12.4.3.1 Growing pharmaceutical industry to fuel uptake of biosimulation
  • 12.4.4 JAPAN
    • 12.4.4.1 Established drug development infrastructure and biomedical research capabilities to support market growth
  • 12.4.5 REST OF ASIA PACIFIC
• 12.5 LATIN AMERICA
  • 12.5.1 MACROECONOMIC OUTLOOK FOR LATIN AMERICA
  • 12.5.2 BRAZIL
    • 12.5.2.1 Advancing biosimulation in region to support market growth
  • 12.5.3 MEXICO
    • 12.5.3.1 Government initiatives to enhance digital health to propel market growth
  • 12.5.4 REST OF LATIN AMERICA
• 12.6 MIDDLE EAST & AFRICA
  • 12.6.1 MACROECONOMIC OUTLOOK FOR MIDDLE EAST & AFRICA
  • 12.6.2 GCC COUNTRIES
    • 12.6.2.1 Increase in healthcare investments to support market growth
  • 12.6.3 REST OF MIDDLE EAST & AFRICA

13 COMPETITIVE LANDSCAPE

• 13.1 INTRODUCTION
• 13.2 KEY PLAYER STRATEGY/RIGHT TO WIN
  • 13.2.1 OVERVIEW OF STRATEGIES ADOPTED BY PLAYERS IN BIOSIMULATION MARKET
• 13.3 REVENUE ANALYSIS, 2019-2023
• 13.4 MARKET SHARE ANALYSIS, 2023
  • 13.4.1 CERTARA, USA (US)
  • 13.4.2 DASSAULT SYSTEMES (FRANCE)
  • 13.4.3 SCHRODINGER, INC. (US)
  • 13.4.4 SIMULATIONS PLUS (US)
  • 13.4.5 ADVANCED CHEMISTRY DEVELOPMENT, INC. (CANADA)
• 13.5 RANKING OF KEY MARKET PLAYERS
• 13.6 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2023
  • 13.6.1 STARS
  • 13.6.2 EMERGING LEADERS
  • 13.6.3 PERVASIVE PLAYERS
  • 13.6.4 PARTICIPANTS
  • 13.6.5 COMPANY FOOTPRINT: KEY PLAYERS, 2023
    • 13.6.5.1 Company footprint
    • 13.6.5.2 Offering footprint
    • 13.6.5.3 Application footprint
    • 13.6.5.4 End-user footprint
    • 13.6.5.5 Region footprint
• 13.7 COMPANY EVALUATION MATRIX: START-UP/SMES, 2023
  • 13.7.1 PROGRESSIVE COMPANIES
  • 13.7.2 RESPONSIVE COMPANIES
  • 13.7.3 DYNAMIC COMPANIES
  • 13.7.4 STARTING BLOCKS
  • 13.7.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2023
• 13.8 COMPANY EVALUATION & FINANCIAL METRICS
• 13.9 BRAND/PRODUCT COMPARISON
• 13.10 COMPETITIVE SCENARIO
  • 13.10.1 PRODUCT LAUNCHES & ENHANCEMENTS
  • 13.10.2 DEALS
  • 13.10.3 EXPANSIONS
  • 13.10.4 OTHER DEVELOPMENTS

14 COMPANY PROFILES

• 14.1 KEY PLAYERS
  • 14.1.1 CERTARA, USA
    • 14.1.1.1 Business overview
    • 14.1.1.2 Products & services offered
    • 14.1.1.3 Recent developments
      • 14.1.1.3.1 Product launches & enhancements
      • 14.1.1.3.2 Deals
    • 14.1.1.4 MnM view
      • 14.1.1.4.1 Right to win
      • 14.1.1.4.2 Strategic choices
      • 14.1.1.4.3 Weaknesses & competitive threats
  • 14.1.2 DASSAULT SYSTEMES
    • 14.1.2.1 Business overview
    • 14.1.2.2 Products & services offered
    • 14.1.2.3 Recent developments
      • 14.1.2.3.1 Deals
    • 14.1.2.4 MnM view
      • 14.1.2.4.1 Right to win
      • 14.1.2.4.2 Strategic choices
      • 14.1.2.4.3 Weaknesses & competitive threats
  • 14.1.3 SCHRODINGER, INC.
    • 14.1.3.1 Business overview
    • 14.1.3.2 Products & services offered
    • 14.1.3.3 Recent developments
      • 14.1.3.3.1 Deals
    • 14.1.3.4 MnM view
      • 14.1.3.4.1 Right to win
      • 14.1.3.4.2 Strategic choices
      • 14.1.3.4.3 Weaknesses & competitive threats
  • 14.1.4 SIMULATIONS PLUS
    • 14.1.4.1 Business overview
    • 14.1.4.2 Products & services offered
    • 14.1.4.3 Recent developments
      • 14.1.4.3.1 Product launches & enhancements
      • 14.1.4.3.2 Deals
      • 14.1.4.3.3 Other developments
  • 14.1.5 ADVANCED CHEMISTRY DEVELOPMENT, INC.
    • 14.1.5.1 Business overview
    • 14.1.5.2 Products & services offered
    • 14.1.5.3 Recent developments
      • 14.1.5.3.1 Product launches & enhancements
      • 14.1.5.3.2 Deals
  • 14.1.6 CHEMICAL COMPUTING GROUP ULC
    • 14.1.6.1 Business overview
    • 14.1.6.2 Products & services offered
    • 14.1.6.3 Recent developments
      • 14.1.6.3.1 Deals
  • 14.1.7 ROSA & CO. LLC
    • 14.1.7.1 Business overview
    • 14.1.7.2 Products & services offered
  • 14.1.8 GENEDATA AG (A DANAHER COMPANY)
    • 14.1.8.1 Business overview
    • 14.1.8.2 Products & services offered
    • 14.1.8.3 Recent developments
      • 14.1.8.3.1 Product launches & enhancements
      • 14.1.8.3.2 Deals
  • 14.1.9 PHYSIOMICS PLC
    • 14.1.9.1 Business overview
    • 14.1.9.2 Products & services offered
    • 14.1.9.3 Recent developments
      • 14.1.9.3.1 Deals
  • 14.1.10 IN SILICO BIOSCIENCES
    • 14.1.10.1 Business overview
    • 14.1.10.2 Products & services offered
  • 14.1.11 ALLUCENT
    • 14.1.11.1 Business overview
    • 14.1.11.2 Products & services offered
    • 14.1.11.3 Recent developments
      • 14.1.11.3.1 Deals
      • 14.1.11.3.2 Expansions
  • 14.1.12 OPENEYE, CADENCE MOLECULAR SCIENCES
    • 14.1.12.1 Business overview
    • 14.1.12.2 Products & services offered
    • 14.1.12.3 Recent developments
      • 14.1.12.3.1 Product enhancements
      • 14.1.12.3.2 Deals
      • 14.1.12.3.3 Expansions
  • 14.1.13 CELLWORKS GROUP, INC.
    • 14.1.13.1 Business overview
    • 14.1.13.2 Products & services offered
    • 14.1.13.3 Recent developments
      • 14.1.13.3.1 Expansions
  • 14.1.14 VERISIM LIFE
    • 14.1.14.1 Business overview
    • 14.1.14.2 Products & services offered
    • 14.1.14.3 Recent developments
      • 14.1.14.3.1 Deals
      • 14.1.14.3.2 Other developments
  • 14.1.15 NETABOLICS
    • 14.1.15.1 Business overview
    • 14.1.15.2 Products & services offered
  • 14.1.16 CHARNWOOD DISCOVERY
    • 14.1.16.1 Business overview
    • 14.1.16.2 Products & services offered
    • 14.1.16.3 Recent developments
      • 14.1.16.3.1 Deals
  • 14.1.17 THE MATHWORKS, INC.
    • 14.1.17.1 Business overview
    • 14.1.17.2 Products & services offered
    • 14.1.17.3 Recent developments
      • 14.1.17.3.1 Product enhancements
  • 14.1.18 ANSYS, INC.
    • 14.1.18.1 Business overview
    • 14.1.18.2 Products & services offered
• 14.2 START-UP/SME PLAYERS
  • 14.2.1 INSTEM GROUP OF COMPANIES
  • 14.2.2 INSILICO MEDICINE
  • 14.2.3 SCM - SOFTWARE CHEMISTRY & MATERIALS
  • 14.2.4 BIOSYMETRICS, INC.
  • 14.2.5 ATOMWISE INC.
  • 14.2.6 INSITRO
  • 14.2.7 CLINITHINK

15 APPENDIX

• 15.1 DISCUSSION GUIDE
• 15.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
• 15.3 CUSTOMIZATION OPTIONS
• 15.4 RELATED REPORTS
• 15.5 AUTHOR DETAILS

List of Tables

• TABLE 1 BIOSIMULATION MARKET: ROLE OF COMPANIES IN ECOSYSTEM
• TABLE 2 BIOSIMULATION MARKET: PORTER'S FIVE FORCES
• TABLE 3 NORTH AMERICA: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
• TABLE 4 EUROPE: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
• TABLE 5 ASIA PACIFIC: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
• TABLE 6 LATIN AMERICA: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
• TABLE 7 MIDDLE EAST & AFRICA: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
• TABLE 8 INDICATIVE PRICING ANALYSIS OF KEY PLAYERS, BY OFFERING
• TABLE 9 BIOSIMULATION MARKET: KEY CONFERENCES AND EVENTS, 2024-2025
• TABLE 10 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF TOP 3 END USERS (%)
• TABLE 11 KEY BUYING CRITERIA FOR TOP 3 END USERS
• TABLE 12 UNMET NEEDS IN BIOSIMULATION MARKET
• TABLE 13 END-USER EXPECTATIONS IN BIOSIMULATION MARKET
• TABLE 14 BIOSIMULATION MARKET, BY OFFERING, 2022-2029 (USD MILLION)
• TABLE 15 BIOSIMULATION SOFTWARE MARKET, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 16 BIOSIMULATION SOFTWARE MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 17 BIOSIMULATION MARKET FOR STANDALONE MODULES, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 18 BIOSIMULATION MARKET FOR STANDALONE MODULES, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 19 BIOSIMULATION MARKET FOR MOLECULAR MODELING & SIMULATION SOFTWARE, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 20 BIOSIMULATION MARKET FOR PK/PD MODELING & SIMULATION SOFTWARE, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 21 BIOSIMULATION MARKET FOR PBPK MODELING & SIMULATION SOFTWARE, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 22 BIOSIMULATION MARKET FOR TOXICITY PREDICTION SOFTWARE, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 23 BIOSIMULATION MARKET FOR CLINICAL TRIAL SIMULATION SOFTWARE, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 24 BIOSIMULATION MARKET FOR OTHER BIOSIMULATION SOFTWARE, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 25 BIOSIMULATION MARKET FOR INTEGRATED SOFTWARE SUITES/PLATFORMS, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 26 BIOSIMULATION SERVICES MARKET, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 27 BIOSIMULATION SERVICES MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 28 BIOSIMULATION MARKET FOR CONSULTING & ADVISORY SERVICES, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 29 BIOSIMULATION MARKET FOR IMPLEMENTATION, TRAINING, AND SUPPORT SERVICES, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 30 BIOSIMULATION MARKET FOR DATA ANALYSIS & INTERPRETATION SERVICES, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 31 BIOSIMULATION MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
• TABLE 32 BIOSIMULATION MARKET FOR DRUG DISCOVERY APPLICATIONS, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 33 BIOSIMULATION MARKET FOR DRUG DISCOVERY APPLICATIONS, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 34 BIOSIMULATION MARKET FOR TARGET IDENTIFICATION & VALIDATION, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 35 BIOSIMULATION MARKET FOR LEAD IDENTIFICATION & OPTIMIZATION, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 36 BIOSIMULATION MARKET FOR DRUG DEVELOPMENT APPLICATIONS, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 37 BIOSIMULATION MARKET FOR DRUG DEVELOPMENT APPLICATIONS, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 38 BIOSIMULATION MARKET FOR PRECLINICAL TESTING, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 39 BIOSIMULATION MARKET FOR PRECLINICAL TESTING, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 40 BIOSIMULATION MARKET FOR PK/PD, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 41 BIOSIMULATION MARKET FOR ADME/TOXICOLOGY, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 42 BIOSIMULATION MARKET FOR CLINICAL TRIALS, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 43 BIOSIMULATION MARKET FOR CLINICAL TRIALS, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 44 BIOSIMULATION MARKET FOR PHASE I CLINICAL TRIALS, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 45 BIOSIMULATION MARKET FOR PHASE II CLINICAL TRIALS, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 46 BIOSIMULATION MARKET FOR PHASE III CLINICAL TRIALS, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 47 BIOSIMULATION MARKET FOR PHASE IV/POST-MARKETING SURVEILLANCE, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 48 BIOSIMULATION MARKET FOR DISEASE MODELING APPLICATIONS, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 49 BIOSIMULATION MARKET FOR MANUFACTURING & SUPPLY CHAIN MANAGEMENT APPLICATIONS, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 50 BIOSIMULATION MARKET FOR MANUFACTURING & SUPPLY CHAIN MANAGEMENT APPLICATIONS, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 51 BIOSIMULATION MARKET FOR PRODUCTION PLANNING & OPTIMIZATION, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 52 BIOSIMULATION MARKET FOR QUALITY CONTROL & PROCESS MONITORING, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 53 BIOSIMULATION MARKET FOR DEMAND FORECASTING & INVENTORY MANAGEMENT, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 54 BIOSIMULATION MARKET FOR RISK MANAGEMENT & CONTINGENCY PLANNING, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 55 BIOSIMULATION MARKET FOR OTHER MANUFACTURING & SUPPLY CHAIN MANAGEMENT APPLICATIONS, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 56 BIOSIMULATION MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 57 BIOSIMULATION MARKET, BY THERAPEUTIC AREA, 2022-2029 (USD MILLION)
• TABLE 58 BIOSIMULATION MARKET FOR ONCOLOGY, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 59 BIOSIMULATION MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 60 BIOSIMULATION MARKET FOR NEUROLOGICAL DISORDERS, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 61 BIOSIMULATION MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 62 BIOSIMULATION MARKET FOR OTHER THERAPEUTIC AREAS, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 63 BIOSIMULATION MARKET, BY REVENUE MODEL, 2022-2029 (USD MILLION)
• TABLE 64 BIOSIMULATION MARKET FOR LICENSE-BASED MODELS, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 65 BIOSIMULATION MARKET FOR SUBSCRIPTION-BASED MODELS, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 66 BIOSIMULATION MARKET FOR SERVICE-BASED MODELS, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 67 BIOSIMULATION MARKET FOR PAY-PER-USE MODELS, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 68 BIOSIMULATION MARKET, BY DEPLOYMENT MODEL, 2022-2029 (USD MILLION)
• TABLE 69 BIOSIMULATION MARKET FOR ON-PREMISE MODELS, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 70 BIOSIMULATION MARKET FOR CLOUD-BASED MODELS, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 71 BIOSIMULATION MARKET FOR HYBRID MODELS, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 72 BIOSIMULATION MARKET, BY END USER, 2022-2029 (USD MILLION)
• TABLE 73 BIOSIMULATION MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 74 BIOSIMULATION MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 75 BIOSIMULATION MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 76 BIOSIMULATION MARKET FOR REGULATORY BODIES, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 77 BIOSIMULATION MARKET FOR OTHER END USERS, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 78 BIOSIMULATION MARKET, BY REGION, 2022-2029 (USD MILLION)
• TABLE 79 NORTH AMERICA: BIOSIMULATION MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 80 NORTH AMERICA: BIOSIMULATION MARKET, BY OFFERING, 2022-2029 (USD MILLION)
• TABLE 81 NORTH AMERICA: BIOSIMULATION SOFTWARE MARKET, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 82 NORTH AMERICA: BIOSIMULATION MARKET FOR STANDALONE MODULES, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 83 NORTH AMERICA: BIOSIMULATION SERVICES MARKET, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 84 NORTH AMERICA: BIOSIMULATION MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
• TABLE 85 NORTH AMERICA: BIOSIMULATION MARKET FOR DRUG DISCOVERY APPLICATIONS, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 86 NORTH AMERICA: BIOSIMULATION MARKET FOR DRUG DEVELOPMENT APPLICATIONS, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 87 NORTH AMERICA: BIOSIMULATION MARKET FOR PRECLINICAL TESTING, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 88 NORTH AMERICA: BIOSIMULATION MARKET FOR CLINICAL TRIALS, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 89 NORTH AMERICA: BIOSIMULATION MARKET FOR MANUFACTURING & SUPPLY CHAIN MANAGEMENT APPLICATIONS, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 90 NORTH AMERICA: BIOSIMULATION MARKET, BY THERAPEUTIC AREA, 2022-2029 (USD MILLION)
• TABLE 91 NORTH AMERICA: BIOSIMULATION MARKET, BY REVENUE MODEL, 2022-2029 (USD MILLION)
• TABLE 92 NORTH AMERICA: BIOSIMULATION MARKET, BY DEPLOYMENT MODEL, 2022-2029 (USD MILLION)
• TABLE 93 NORTH AMERICA: BIOSIMULATION MARKET, BY END USER, 2022-2029 (USD MILLION)
• TABLE 94 US: BIOSIMULATION MARKET, BY OFFERING, 2022-2029 (USD MILLION)
• TABLE 95 US: BIOSIMULATION SOFTWARE MARKET, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 96 US: BIOSIMULATION MARKET FOR STANDALONE MODULES, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 97 US: BIOSIMULATION SERVICES MARKET, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 98 US: BIOSIMULATION MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
• TABLE 99 US: BIOSIMULATION MARKET FOR DRUG DISCOVERY APPLICATIONS, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 100 US: BIOSIMULATION MARKET FOR DRUG DEVELOPMENT APPLICATIONS, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 101 US: BIOSIMULATION MARKET FOR PRECLINICAL TESTING, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 102 US: BIOSIMULATION MARKET FOR CLINICAL TRIALS, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 103 US: BIOSIMULATION MARKET FOR MANUFACTURING & SUPPLY CHAIN MANAGEMENT APPLICATIONS, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 104 US: BIOSIMULATION MARKET, BY THERAPEUTIC AREA, 2022-2029 (USD MILLION)
• TABLE 105 US: BIOSIMULATION MARKET, BY REVENUE MODEL, 2022-2029 (USD MILLION)
• TABLE 106 US: BIOSIMULATION MARKET, BY DEPLOYMENT MODEL, 2022-2029 (USD MILLION)
• TABLE 107 US: BIOSIMULATION MARKET, BY END USER, 2022-2029 (USD MILLION)
• TABLE 108 CANADA: BIOSIMULATION MARKET, BY OFFERING, 2022-2029 (USD MILLION)
• TABLE 109 CANADA: BIOSIMULATION SOFTWARE MARKET, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 110 CANADA: BIOSIMULATION MARKET FOR STANDALONE MODULES, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 111 CANADA: BIOSIMULATION SERVICES MARKET, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 112 CANADA: BIOSIMULATION MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
• TABLE 113 CANADA: BIOSIMULATION MARKET FOR DRUG DISCOVERY APPLICATIONS, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 114 CANADA: BIOSIMULATION MARKET FOR DRUG DEVELOPMENT APPLICATIONS, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 115 CANADA: BIOSIMULATION MARKET FOR PRECLINICAL TESTING, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 116 CANADA: BIOSIMULATION MARKET FOR CLINICAL TRIALS, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 117 CANADA: BIOSIMULATION MARKET FOR MANUFACTURING & SUPPLY CHAIN MANAGEMENT APPLICATIONS, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 118 CANADA: BIOSIMULATION MARKET, BY THERAPEUTIC AREA, 2022-2029 (USD MILLION)
• TABLE 119 CANADA: BIOSIMULATION MARKET, BY REVENUE MODEL, 2022-2029 (USD MILLION)
• TABLE 120 CANADA: BIOSIMULATION MARKET, BY DEPLOYMENT MODEL, 2022-2029 (USD MILLION)
• TABLE 121 CANADA: BIOSIMULATION MARKET, BY END USER, 2022-2029 (USD MILLION)
• TABLE 122 EUROPE: BIOSIMULATION MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 123 EUROPE: BIOSIMULATION MARKET, BY OFFERING, 2022-2029 (USD MILLION)
• TABLE 124 EUROPE: BIOSIMULATION SOFTWARE MARKET, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 125 EUROPE: BIOSIMULATION MARKET FOR STANDALONE MODULES, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 126 EUROPE: BIOSIMULATION SERVICES MARKET, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 127 EUROPE: BIOSIMULATION MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
• TABLE 128 EUROPE: BIOSIMULATION MARKET FOR DRUG DISCOVERY APPLICATIONS, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 129 EUROPE: BIOSIMULATION MARKET FOR DRUG DEVELOPMENT APPLICATIONS, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 130 EUROPE: BIOSIMULATION MARKET FOR PRECLINICAL TESTING, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 131 EUROPE: BIOSIMULATION MARKET FOR CLINICAL TRIALS, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 132 EUROPE: BIOSIMULATION MARKET FOR MANUFACTURING & SUPPLY CHAIN MANAGEMENT APPLICATIONS, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 133 EUROPE: BIOSIMULATION MARKET, BY THERAPEUTIC AREA, 2022-2029 (USD MILLION)
• TABLE 134 EUROPE: BIOSIMULATION MARKET, BY REVENUE MODEL, 2022-2029 (USD MILLION)
• TABLE 135 EUROPE: BIOSIMULATION MARKET, BY DEPLOYMENT MODEL, 2022-2029 (USD MILLION)
• TABLE 136 EUROPE: BIOSIMULATION MARKET, BY END USER, 2022-2029 (USD MILLION)
• TABLE 137 GERMANY: BIOSIMULATION MARKET, BY OFFERING, 2022-2029 (USD MILLION)
• TABLE 138 GERMANY: BIOSIMULATION SOFTWARE MARKET, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 139 GERMANY: BIOSIMULATION MARKET FOR STANDALONE MODULES, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 140 GERMANY: BIOSIMULATION SERVICES MARKET, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 141 GERMANY: BIOSIMULATION MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
• TABLE 142 GERMANY: BIOSIMULATION MARKET FOR DRUG DISCOVERY APPLICATIONS, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 143 GERMANY: BIOSIMULATION MARKET FOR DRUG DEVELOPMENT APPLICATIONS, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 144 GERMANY: BIOSIMULATION MARKET FOR PRECLINICAL TESTING, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 145 GERMANY: BIOSIMULATION MARKET FOR CLINICAL TRIALS, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 146 GERMANY: BIOSIMULATION MARKET FOR MANUFACTURING & SUPPLY CHAIN MANAGEMENT APPLICATIONS, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 147 GERMANY: BIOSIMULATION MARKET, BY THERAPEUTIC AREA, 2022-2029 (USD MILLION)
• TABLE 148 GERMANY: BIOSIMULATION MARKET, BY REVENUE MODEL, 2022-2029 (USD MILLION)
• TABLE 149 GERMANY: BIOSIMULATION MARKET, BY DEPLOYMENT MODEL, 2022-2029 (USD MILLION)
• TABLE 150 GERMANY: BIOSIMULATION MARKET, BY END USER, 2022-2029 (USD MILLION)
• TABLE 151 UK: BIOSIMULATION MARKET, BY OFFERING, 2022-2029 (USD MILLION)
• TABLE 152 UK: BIOSIMULATION SOFTWARE MARKET, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 153 UK: BIOSIMULATION MARKET FOR STANDALONE MODULES, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 154 UK: BIOSIMULATION SERVICES MARKET, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 155 UK: BIOSIMULATION MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
• TABLE 156 UK: BIOSIMULATION MARKET FOR DRUG DISCOVERY APPLICATIONS, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 157 UK: BIOSIMULATION MARKET FOR DRUG DEVELOPMENT APPLICATIONS, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 158 UK: BIOSIMULATION MARKET FOR PRECLINICAL TESTING, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 159 UK: BIOSIMULATION MARKET FOR CLINICAL TRIALS, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 160 UK: BIOSIMULATION MARKET FOR MANUFACTURING & SUPPLY CHAIN MANAGEMENT APPLICATIONS, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 161 UK: BIOSIMULATION MARKET, BY THERAPEUTIC AREA, 2022-2029 (USD MILLION)
• TABLE 162 UK: BIOSIMULATION MARKET, BY REVENUE MODEL, 2022-2029 (USD MILLION)
• TABLE 163 UK: BIOSIMULATION MARKET, BY DEPLOYMENT MODEL, 2022-2029 (USD MILLION)
• TABLE 164 UK: BIOSIMULATION MARKET, BY END USER, 2022-2029 (USD MILLION)
• TABLE 165 FRANCE: BIOSIMULATION MARKET, BY OFFERING, 2022-2029 (USD MILLION)
• TABLE 166 FRANCE: BIOSIMULATION SOFTWARE MARKET, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 167 FRANCE: BIOSIMULATION MARKET FOR STANDALONE MODULES, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 168 FRANCE: BIOSIMULATION SERVICES MARKET, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 169 FRANCE: BIOSIMULATION MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
• TABLE 170 FRANCE: BIOSIMULATION MARKET FOR DRUG DISCOVERY APPLICATIONS, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 171 FRANCE: BIOSIMULATION MARKET FOR DRUG DEVELOPMENT APPLICATIONS, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 172 FRANCE: BIOSIMULATION MARKET FOR PRECLINICAL TESTING, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 173 FRANCE: BIOSIMULATION MARKET FOR CLINICAL TRIALS, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 174 FRANCE: BIOSIMULATION MARKET FOR MANUFACTURING & SUPPLY CHAIN MANAGEMENT APPLICATIONS, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 175 FRANCE: BIOSIMULATION MARKET, BY THERAPEUTIC AREA, 2022-2029 (USD MILLION)
• TABLE 176 FRANCE: BIOSIMULATION MARKET, BY REVENUE MODEL, 2022-2029 (USD MILLION)
• TABLE 177 FRANCE: BIOSIMULATION MARKET, BY DEPLOYMENT MODEL, 2022-2029 (USD MILLION)
• TABLE 178 FRANCE: BIOSIMULATION MARKET, BY END USER, 2022-2029 (USD MILLION)
• TABLE 179 ITALY: BIOSIMULATION MARKET, BY OFFERING, 2022-2029 (USD MILLION)
• TABLE 180 ITALY: BIOSIMULATION SOFTWARE MARKET, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 181 ITALY: BIOSIMULATION MARKET FOR STANDALONE MODULES, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 182 ITALY: BIOSIMULATION SERVICES MARKET, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 183 ITALY: BIOSIMULATION MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
• TABLE 184 ITALY: BIOSIMULATION MARKET FOR DRUG DISCOVERY APPLICATIONS, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 185 ITALY: BIOSIMULATION MARKET FOR DRUG DEVELOPMENT APPLICATIONS, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 186 ITALY: BIOSIMULATION MARKET FOR PRECLINICAL TESTING, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 187 ITALY: BIOSIMULATION MARKET FOR CLINICAL TRIALS, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 188 ITALY: BIOSIMULATION MARKET FOR MANUFACTURING & SUPPLY CHAIN MANAGEMENT APPLICATIONS, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 189 ITALY: BIOSIMULATION MARKET, BY THERAPEUTIC AREA, 2022-2029 (USD MILLION)
• TABLE 190 ITALY: BIOSIMULATION MARKET, BY REVENUE MODEL, 2022-2029 (USD MILLION)
• TABLE 191 ITALY: BIOSIMULATION MARKET, BY DEPLOYMENT MODEL, 2022-2029 (USD MILLION)
• TABLE 192 ITALY: BIOSIMULATION MARKET, BY END USER, 2022-2029 (USD MILLION)
• TABLE 193 SPAIN: BIOSIMULATION MARKET, BY OFFERING, 2022-2029 (USD MILLION)
• TABLE 194 SPAIN: BIOSIMULATION SOFTWARE MARKET, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 195 SPAIN: BIOSIMULATION MARKET FOR STANDALONE MODULES, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 196 SPAIN: BIOSIMULATION SERVICES MARKET, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 197 SPAIN: BIOSIMULATION MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
• TABLE 198 SPAIN: BIOSIMULATION MARKET FOR DRUG DISCOVERY APPLICATIONS, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 199 SPAIN: BIOSIMULATION MARKET FOR DRUG DEVELOPMENT APPLICATIONS, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 200 SPAIN: BIOSIMULATION MARKET FOR PRECLINICAL TESTING, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 201 SPAIN: BIOSIMULATION MARKET FOR CLINICAL TRIALS, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 202 SPAIN: BIOSIMULATION MARKET FOR MANUFACTURING & SUPPLY CHAIN MANAGEMENT APPLICATIONS, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 203 SPAIN: BIOSIMULATION MARKET, BY THERAPEUTIC AREA, 2022-2029 (USD MILLION)
• TABLE 204 SPAIN: BIOSIMULATION MARKET, BY REVENUE MODEL, 2022-2029 (USD MILLION)
• TABLE 205 SPAIN: BIOSIMULATION MARKET, BY DEPLOYMENT MODEL, 2022-2029 (USD MILLION)
• TABLE 206 SPAIN: BIOSIMULATION MARKET, BY END USER, 2022-2029 (USD MILLION)
• TABLE 207 REST OF EUROPE: BIOSIMULATION MARKET, BY OFFERING, 2022-2029 (USD MILLION)
• TABLE 208 REST OF EUROPE: BIOSIMULATION SOFTWARE MARKET, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 209 REST OF EUROPE: BIOSIMULATION MARKET FOR STANDALONE MODULES, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 210 REST OF EUROPE: BIOSIMULATION SERVICES MARKET, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 211 REST OF EUROPE: BIOSIMULATION MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
• TABLE 212 REST OF EUROPE: BIOSIMULATION MARKET FOR DRUG DISCOVERY APPLICATIONS, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 213 REST OF EUROPE: BIOSIMULATION MARKET FOR DRUG DEVELOPMENT APPLICATIONS, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 214 REST OF EUROPE: BIOSIMULATION MARKET FOR PRECLINICAL TESTING, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 215 REST OF EUROPE: BIOSIMULATION MARKET FOR CLINICAL TRIALS, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 216 REST OF EUROPE: BIOSIMULATION MARKET FOR MANUFACTURING & SUPPLY CHAIN MANAGEMENT APPLICATIONS, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 217 REST OF EUROPE: BIOSIMULATION MARKET, BY THERAPEUTIC AREA, 2022-2029 (USD MILLION)
• TABLE 218 REST OF EUROPE: BIOSIMULATION MARKET, BY REVENUE MODEL, 2022-2029 (USD MILLION)
• TABLE 219 REST OF EUROPE: BIOSIMULATION MARKET, BY DEPLOYMENT MODEL, 2022-2029 (USD MILLION)
• TABLE 220 REST OF EUROPE: BIOSIMULATION MARKET, BY END USER, 2022-2029 (USD MILLION)
• TABLE 221 ASIA PACIFIC: BIOSIMULATION MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 222 ASIA PACIFIC: BIOSIMULATION MARKET, BY OFFERING, 2022-2029 (USD MILLION)
• TABLE 223 ASIA PACIFIC: BIOSIMULATION SOFTWARE MARKET, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 224 ASIA PACIFIC: BIOSIMULATION MARKET FOR STANDALONE MODULES, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 225 ASIA PACIFIC: BIOSIMULATION SERVICES MARKET, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 226 ASIA PACIFIC: BIOSIMULATION MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
• TABLE 227 ASIA PACIFIC: BIOSIMULATION MARKET FOR DRUG DISCOVERY APPLICATIONS, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 228 ASIA PACIFIC: BIOSIMULATION MARKET FOR DRUG DEVELOPMENT APPLICATIONS, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 229 ASIA PACIFIC: BIOSIMULATION MARKET FOR PRECLINICAL TESTING, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 230 ASIA PACIFIC: BIOSIMULATION MARKET FOR CLINICAL TRIALS, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 231 ASIA PACIFIC: BIOSIMULATION MARKET FOR MANUFACTURING & SUPPLY CHAIN MANAGEMENT APPLICATIONS, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 232 ASIA PACIFIC: BIOSIMULATION MARKET, BY THERAPEUTIC AREA, 2022-2029 (USD MILLION)
• TABLE 233 ASIA PACIFIC: BIOSIMULATION MARKET, BY REVENUE MODEL, 2022-2029 (USD MILLION)
• TABLE 234 ASIA PACIFIC: BIOSIMULATION MARKET, BY DEPLOYMENT MODEL, 2022-2029 (USD MILLION)
• TABLE 235 ASIA PACIFIC: BIOSIMULATION MARKET, BY END USER, 2022-2029 (USD MILLION)
• TABLE 236 CHINA: BIOSIMULATION MARKET, BY OFFERING, 2022-2029 (USD MILLION)
• TABLE 237 CHINA: BIOSIMULATION SOFTWARE MARKET, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 238 CHINA: BIOSIMULATION MARKET FOR STANDALONE MODULES, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 239 CHINA: BIOSIMULATION SERVICES MARKET, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 240 CHINA: BIOSIMULATION MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
• TABLE 241 CHINA: BIOSIMULATION MARKET FOR DRUG DISCOVERY APPLICATIONS, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 242 CHINA: BIOSIMULATION MARKET FOR DRUG DEVELOPMENT APPLICATIONS, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 243 CHINA: BIOSIMULATION MARKET FOR PRECLINICAL TESTING, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 244 CHINA: BIOSIMULATION MARKET FOR CLINICAL TRIALS, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 245 CHINA: BIOSIMULATION MARKET FOR MANUFACTURING & SUPPLY CHAIN MANAGEMENT APPLICATIONS, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 246 CHINA: BIOSIMULATION MARKET, BY THERAPEUTIC AREA, 2022-2029 (USD MILLION)
• TABLE 247 CHINA: BIOSIMULATION MARKET, BY REVENUE MODEL, 2022-2029 (USD MILLION)
• TABLE 248 CHINA: BIOSIMULATION MARKET, BY DEPLOYMENT MODEL, 2022-2029 (USD MILLION)
• TABLE 249 CHINA: BIOSIMULATION MARKET, BY END USER, 2022-2029 (USD MILLION)
• TABLE 250 INDIA: BIOSIMULATION MARKET, BY OFFERING, 2022-2029 (USD MILLION)
• TABLE 251 INDIA: BIOSIMULATION SOFTWARE MARKET, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 252 INDIA: BIOSIMULATION MARKET FOR STANDALONE MODULES, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 253 INDIA: BIOSIMULATION SERVICES MARKET, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 254 INDIA: BIOSIMULATION MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
• TABLE 255 INDIA: BIOSIMULATION MARKET FOR DRUG DISCOVERY APPLICATIONS, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 256 INDIA: BIOSIMULATION MARKET FOR DRUG DEVELOPMENT APPLICATIONS, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 257 INDIA: BIOSIMULATION MARKET FOR PRECLINICAL TESTING, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 258 INDIA: BIOSIMULATION MARKET FOR CLINICAL TRIALS, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 259 INDIA: BIOSIMULATION MARKET FOR MANUFACTURING & SUPPLY CHAIN MANAGEMENT APPLICATIONS, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 260 INDIA: BIOSIMULATION MARKET, BY THERAPEUTIC AREA, 2022-2029 (USD MILLION)
• TABLE 261 INDIA: BIOSIMULATION MARKET, BY REVENUE MODEL, 2022-2029 (USD MILLION)
• TABLE 262 INDIA: BIOSIMULATION MARKET, BY DEPLOYMENT MODEL, 2022-2029 (USD MILLION)
• TABLE 263 INDIA: BIOSIMULATION MARKET, BY END USER, 2022-2029 (USD MILLION)
• TABLE 264 JAPAN: BIOSIMULATION MARKET, BY OFFERING, 2022-2029 (USD MILLION)
• TABLE 265 JAPAN: BIOSIMULATION SOFTWARE MARKET, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 266 JAPAN: BIOSIMULATION MARKET FOR STANDALONE MODULES, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 267 JAPAN: BIOSIMULATION SERVICES MARKET, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 268 JAPAN: BIOSIMULATION MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
• TABLE 269 JAPAN: BIOSIMULATION MARKET FOR DRUG DISCOVERY APPLICATIONS, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 270 JAPAN: BIOSIMULATION MARKET FOR DRUG DEVELOPMENT APPLICATIONS, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 271 JAPAN: BIOSIMULATION MARKET FOR PRECLINICAL TESTING, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 272 JAPAN: BIOSIMULATION MARKET FOR CLINICAL TRIALS, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 273 JAPAN: BIOSIMULATION MARKET FOR MANUFACTURING & SUPPLY CHAIN MANAGEMENT APPLICATIONS, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 274 JAPAN: BIOSIMULATION MARKET, BY THERAPEUTIC AREA, 2022-2029 (USD MILLION)
• TABLE 275 JAPAN: BIOSIMULATION MARKET, BY REVENUE MODEL, 2022-2029 (USD MILLION)
• TABLE 276 JAPAN: BIOSIMULATION MARKET, BY DEPLOYMENT MODEL, 2022-2029 (USD MILLION)
• TABLE 277 JAPAN: BIOSIMULATION MARKET, BY END USER, 2022-2029 (USD MILLION)
• TABLE 278 REST OF ASIA PACIFIC: BIOSIMULATION MARKET, BY OFFERING, 2022-2029 (USD MILLION)
• TABLE 279 REST OF ASIA PACIFIC: BIOSIMULATION SOFTWARE MARKET, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 280 REST OF ASIA PACIFIC: BIOSIMULATION MARKET FOR STANDALONE MODULES, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 281 REST OF ASIA PACIFIC: BIOSIMULATION SERVICES MARKET, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 282 REST OF ASIA PACIFIC: BIOSIMULATION MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
• TABLE 283 REST OF ASIA PACIFIC: BIOSIMULATION MARKET FOR DRUG DISCOVERY APPLICATIONS, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 284 REST OF ASIA PACIFIC: BIOSIMULATION MARKET FOR DRUG DEVELOPMENT APPLICATIONS, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 285 REST OF ASIA PACIFIC: BIOSIMULATION MARKET FOR PRECLINICAL TESTING, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 286 REST OF ASIA PACIFIC: BIOSIMULATION MARKET FOR CLINICAL TRIALS, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 287 REST OF ASIA PACIFIC: BIOSIMULATION MARKET FOR MANUFACTURING & SUPPLY CHAIN MANAGEMENT APPLICATIONS, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 288 REST OF ASIA PACIFIC: BIOSIMULATION MARKET, BY THERAPEUTIC AREA, 2022-2029 (USD MILLION)
• TABLE 289 REST OF ASIA PACIFIC: BIOSIMULATION MARKET, BY REVENUE MODEL, 2022-2029 (USD MILLION)
• TABLE 290 REST OF ASIA PACIFIC: BIOSIMULATION MARKET, BY DEPLOYMENT MODEL, 2022-2029 (USD MILLION)
• TABLE 291 REST OF ASIA PACIFIC: BIOSIMULATION MARKET, BY END USER, 2022-2029 (USD MILLION)
• TABLE 292 LATIN AMERICA: BIOSIMULATION MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 293 LATIN AMERICA: BIOSIMULATION MARKET, BY OFFERING, 2022-2029 (USD MILLION)
• TABLE 294 LATIN AMERICA: BIOSIMULATION SOFTWARE MARKET, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 295 LATIN AMERICA: BIOSIMULATION MARKET FOR STANDALONE MODULES, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 296 LATIN AMERICA: BIOSIMULATION SERVICES MARKET, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 297 LATIN AMERICA: BIOSIMULATION MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
• TABLE 298 LATIN AMERICA: BIOSIMULATION MARKET FOR DRUG DISCOVERY APPLICATIONS, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 299 LATIN AMERICA: BIOSIMULATION MARKET FOR DRUG DEVELOPMENT APPLICATIONS, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 300 LATIN AMERICA: BIOSIMULATION MARKET FOR PRECLINICAL TESTING, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 301 LATIN AMERICA: BIOSIMULATION MARKET FOR CLINICAL TRIALS, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 302 LATIN AMERICA: BIOSIMULATION MARKET FOR MANUFACTURING & SUPPLY CHAIN MANAGEMENT APPLICATIONS, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 303 LATIN AMERICA: BIOSIMULATION MARKET, BY THERAPEUTIC AREA, 2022-2029 (USD MILLION)
• TABLE 304 LATIN AMERICA: BIOSIMULATION MARKET, BY REVENUE MODEL, 2022-2029 (USD MILLION)
• TABLE 305 LATIN AMERICA: BIOSIMULATION MARKET, BY DEPLOYMENT MODEL, 2022-2029 (USD MILLION)
• TABLE 306 LATIN AMERICA: BIOSIMULATION MARKET, BY END USER, 2022-2029 (USD MILLION)
• TABLE 307 BRAZIL: BIOSIMULATION MARKET, BY OFFERING, 2022-2029 (USD MILLION)
• TABLE 308 BRAZIL: BIOSIMULATION SOFTWARE MARKET, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 309 BRAZIL: BIOSIMULATION MARKET FOR STANDALONE MODULES, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 310 BRAZIL: BIOSIMULATION SERVICES MARKET, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 311 BRAZIL: BIOSIMULATION MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
• TABLE 312 BRAZIL: BIOSIMULATION MARKET FOR DRUG DISCOVERY APPLICATIONS, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 313 BRAZIL: BIOSIMULATION MARKET FOR DRUG DEVELOPMENT APPLICATIONS, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 314 BRAZIL: BIOSIMULATION MARKET FOR PRECLINICAL TESTING, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 315 BRAZIL: BIOSIMULATION MARKET FOR CLINICAL TRIALS, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 316 BRAZIL: BIOSIMULATION MARKET FOR MANUFACTURING & SUPPLY CHAIN MANAGEMENT APPLICATIONS, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 317 BRAZIL: BIOSIMULATION MARKET, BY THERAPEUTIC AREA, 2022-2029 (USD MILLION)
• TABLE 318 BRAZIL: BIOSIMULATION MARKET, BY REVENUE MODEL, 2022-2029 (USD MILLION)
• TABLE 319 BRAZIL: BIOSIMULATION MARKET, BY DEPLOYMENT MODEL, 2022-2029 (USD MILLION)
• TABLE 320 BRAZIL: BIOSIMULATION MARKET, BY END USER, 2022-2029 (USD MILLION)
• TABLE 321 MEXICO: BIOSIMULATION MARKET, BY OFFERING, 2022-2029 (USD MILLION)
• TABLE 322 MEXICO: BIOSIMULATION SOFTWARE MARKET, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 323 MEXICO: BIOSIMULATION MARKET FOR STANDALONE MODULES, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 324 MEXICO: BIOSIMULATION SERVICES MARKET, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 325 MEXICO: BIOSIMULATION MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
• TABLE 326 MEXICO: BIOSIMULATION MARKET FOR DRUG DISCOVERY APPLICATIONS, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 327 MEXICO: BIOSIMULATION MARKET FOR DRUG DEVELOPMENT APPLICATIONS, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 328 MEXICO: BIOSIMULATION MARKET FOR PRECLINICAL TESTING, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 329 MEXICO: BIOSIMULATION MARKET FOR CLINICAL TRIALS, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 330 MEXICO: BIOSIMULATION MARKET FOR MANUFACTURING & SUPPLY CHAIN MANAGEMENT APPLICATIONS, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 331 MEXICO: BIOSIMULATION MARKET, BY THERAPEUTIC AREA, 2022-2029 (USD MILLION)
• TABLE 332 MEXICO: BIOSIMULATION MARKET, BY REVENUE MODEL, 2022-2029 (USD MILLION)
• TABLE 333 MEXICO: BIOSIMULATION MARKET, BY DEPLOYMENT MODEL, 2022-2029 (USD MILLION)
• TABLE 334 MEXICO: BIOSIMULATION MARKET, BY END USER, 2022-2029 (USD MILLION)
• TABLE 335 REST OF LATIN AMERICA: BIOSIMULATION MARKET, BY OFFERING, 2022-2029 (USD MILLION)
• TABLE 336 REST OF LATIN AMERICA: BIOSIMULATION SOFTWARE MARKET, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 337 REST OF LATIN AMERICA: BIOSIMULATION MARKET FOR STANDALONE MODULES, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 338 REST OF LATIN AMERICA: BIOSIMULATION SERVICES MARKET, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 339 REST OF LATIN AMERICA: BIOSIMULATION MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
• TABLE 340 REST OF LATIN AMERICA: BIOSIMULATION MARKET FOR DRUG DISCOVERY APPLICATIONS, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 341 REST OF LATIN AMERICA: BIOSIMULATION MARKET FOR DRUG DEVELOPMENT APPLICATIONS, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 342 REST OF LATIN AMERICA: BIOSIMULATION MARKET FOR PRECLINICAL TESTING, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 343 REST OF LATIN AMERICA: BIOSIMULATION MARKET FOR CLINICAL TRIALS, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 344 REST OF LATIN AMERICA: BIOSIMULATION MARKET FOR MANUFACTURING & SUPPLY CHAIN MANAGEMENT APPLICATIONS, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 345 REST OF LATIN AMERICA: BIOSIMULATION MARKET, BY THERAPEUTIC AREA, 2022-2029 (USD MILLION)
• TABLE 346 REST OF LATIN AMERICA: BIOSIMULATION MARKET, BY REVENUE MODEL, 2022-2029 (USD MILLION)
• TABLE 347 REST OF LATIN AMERICA: BIOSIMULATION MARKET, BY DEPLOYMENT MODEL, 2022-2029 (USD MILLION)
• TABLE 348 REST OF LATIN AMERICA: BIOSIMULATION MARKET, BY END USER, 2022-2029 (USD MILLION)
• TABLE 349 MIDDLE EAST & AFRICA: BIOSIMULATION MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
• TABLE 350 MIDDLE EAST & AFRICA: BIOSIMULATION MARKET, BY OFFERING, 2022-2029 (USD MILLION)
• TABLE 351 MIDDLE EAST & AFRICA: BIOSIMULATION SOFTWARE MARKET, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 352 MIDDLE EAST & AFRICA: BIOSIMULATION MARKET FOR STANDALONE MODULES, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 353 MIDDLE EAST & AFRICA: BIOSIMULATION SERVICES MARKET, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 354 MIDDLE EAST & AFRICA: BIOSIMULATION MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
• TABLE 355 MIDDLE EAST & AFRICA: BIOSIMULATION MARKET FOR DRUG DISCOVERY APPLICATIONS, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 356 MIDDLE EAST & AFRICA: BIOSIMULATION MARKET FOR DRUG DEVELOPMENT APPLICATIONS, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 357 MIDDLE EAST & AFRICA: BIOSIMULATION MARKET FOR PRECLINICAL TESTING, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 358 MIDDLE EAST & AFRICA: BIOSIMULATION MARKET FOR CLINICAL TRIALS, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 359 MIDDLE EAST & AFRICA: BIOSIMULATION MARKET FOR MANUFACTURING & SUPPLY CHAIN MANAGEMENT APPLICATIONS, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 360 MIDDLE EAST & AFRICA: BIOSIMULATION MARKET, BY THERAPEUTIC AREA, 2022-2029 (USD MILLION)
• TABLE 361 MIDDLE EAST & AFRICA: BIOSIMULATION MARKET, BY REVENUE MODEL, 2022-2029 (USD MILLION)
• TABLE 362 MIDDLE EAST & AFRICA: BIOSIMULATION MARKET, BY DEPLOYMENT MODEL, 2022-2029 (USD MILLION)
• TABLE 363 MIDDLE EAST & AFRICA: BIOSIMULATION MARKET, BY END USER, 2022-2029 (USD MILLION)
• TABLE 364 GCC COUNTRIES: BIOSIMULATION MARKET, BY OFFERING, 2022-2029 (USD MILLION)
• TABLE 365 GCC COUNTRIES: BIOSIMULATION SOFTWARE MARKET, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 366 GCC COUNTRIES: BIOSIMULATION MARKET FOR STANDALONE MODULES, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 367 GCC COUNTRIES: BIOSIMULATION SERVICES MARKET, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 368 GCC COUNTRIES: BIOSIMULATION MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
• TABLE 369 GCC COUNTRIES: BIOSIMULATION MARKET FOR DRUG DISCOVERY APPLICATIONS, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 370 GCC COUNTRIES: BIOSIMULATION MARKET FOR DRUG DEVELOPMENT APPLICATIONS, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 371 GCC COUNTRIES: BIOSIMULATION MARKET FOR PRECLINICAL TESTING, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 372 GCC COUNTRIES: BIOSIMULATION MARKET FOR CLINICAL TRIALS, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 373 GCC COUNTRIES: BIOSIMULATION MARKET FOR MANUFACTURING & SUPPLY CHAIN MANAGEMENT APPLICATIONS, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 374 GCC COUNTRIES: BIOSIMULATION MARKET, BY THERAPEUTIC AREA, 2022-2029 (USD MILLION)
• TABLE 375 GCC COUNTRIES: BIOSIMULATION MARKET, BY REVENUE MODEL, 2022-2029 (USD MILLION)
• TABLE 376 GCC COUNTRIES: BIOSIMULATION MARKET, BY DEPLOYMENT MODEL, 2022-2029 (USD MILLION)
• TABLE 377 GCC COUNTRIES: BIOSIMULATION MARKET, BY END USER, 2022-2029 (USD MILLION)
• TABLE 378 REST OF MIDDLE EAST & AFRICA: BIOSIMULATION MARKET, BY OFFERING, 2022-2029 (USD MILLION)
• TABLE 379 REST OF MIDDLE EAST & AFRICA: BIOSIMULATION SOFTWARE MARKET, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 380 REST OF MIDDLE EAST & AFRICA: BIOSIMULATION MARKET FOR STANDALONE MODULES, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 381 REST OF MIDDLE EAST & AFRICA: BIOSIMULATION SERVICES MARKET, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 382 REST OF MIDDLE EAST & AFRICA: BIOSIMULATION MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
• TABLE 383 REST OF MIDDLE EAST & AFRICA: BIOSIMULATION MARKET FOR DRUG DISCOVERY APPLICATIONS, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 384 REST OF MIDDLE EAST & AFRICA: BIOSIMULATION MARKET FOR DRUG DEVELOPMENT APPLICATIONS, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 385 REST OF MIDDLE EAST & AFRICA: BIOSIMULATION MARKET FOR PRECLINICAL TESTING, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 386 REST OF MIDDLE EAST & AFRICA: BIOSIMULATION MARKET FOR CLINICAL TRIALS, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 387 REST OF MIDDLE EAST & AFRICA: BIOSIMULATION MARKET FOR MANUFACTURING & SUPPLY CHAIN MANAGEMENT APPLICATIONS, BY TYPE, 2022-2029 (USD MILLION)
• TABLE 388 REST OF MIDDLE EAST & AFRICA: BIOSIMULATION MARKET, BY THERAPEUTIC AREA, 2022-2029 (USD MILLION)
• TABLE 389 REST OF MIDDLE EAST & AFRICA: BIOSIMULATION MARKET, BY REVENUE MODEL, 2022-2029 (USD MILLION)
• TABLE 390 REST OF MIDDLE EAST & AFRICA NORTH AMERICA: BIOSIMULATION MARKET, BY DEPLOYMENT MODEL, 2022-2029 (USD MILLION)
• TABLE 391 REST OF MIDDLE EAST & AFRICA: BIOSIMULATION MARKET, BY END USER, 2022-2029 (USD MILLION)
• TABLE 392 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN BIOSIMULATION MARKET
• TABLE 393 BIOSIMULATION MARKET: DEGREE OF COMPETITION
• TABLE 394 BIOSIMULATION MARKET: OFFERING FOOTPRINT
• TABLE 395 BIOSIMULATION MARKET: APPLICATION FOOTPRINT
• TABLE 396 BIOSIMULATION MARKET: END-USER FOOTPRINT
• TABLE 397 BIOSIMULATION MARKET: REGION FOOTPRINT
• TABLE 398 BIOSIMULATION MARKET: DETAILED LIST OF KEY START-UPS/SMES
• TABLE 399 BIOSIMULATION MARKET: COMPETITIVE BENCHMARKING OF KEY EMERGING PLAYERS/STARTUPS
• TABLE 400 BIOSIMULATION MARKET: PRODUCT LAUNCHES & ENHANCEMENTS, JANUARY 2021-OCTOBER 2024
• TABLE 401 BIOSIMULATION MARKET: DEALS, JANUARY 2021-OCTOBER 2024
• TABLE 402 BIOSIMULATION MARKET: EXPANSIONS, JANUARY 2021-OCTOBER 2024
• TABLE 403 BIOSIMULATION MARKET: OTHER DEVELOPMENTS, JANUARY 2021-OCTOBER 2024
• TABLE 404 CERTARA, USA: COMPANY OVERVIEW
• TABLE 405 CERTARA, USA: PRODUCTS & SERVICES OFFERED
• TABLE 406 CERTARA, USA: PRODUCT LAUNCHES & ENHANCEMENTS, JANUARY 2021-OCTOBER 2024
• TABLE 407 CERTARA, USA: DEALS, JANUARY 2021-OCTOBER 2024
• TABLE 408 DASSAULT SYSTEMES: COMPANY OVERVIEW
• TABLE 409 DASSAULT SYSTEMES: PRODUCTS & SERVICES OFFERED
• TABLE 410 DASSAULT SYSTEMES: DEALS, JANUARY 2021-JUNE 2024
• TABLE 411 SCHRODINGER, INC.: COMPANY OVERVIEW
• TABLE 412 SCHRODINGER, INC.: PRODUCTS & SERVICES OFFERED
• TABLE 413 SCHRODINGER, INC.: DEALS, JANUARY 2021-OCTOBER 2024
• TABLE 414 SIMULATIONS PLUS: COMPANY OVERVIEW
• TABLE 415 SIMULATIONS PLUS: PRODUCTS & SERVICES OFFERED
• TABLE 416 SIMULATIONS PLUS: PRODUCT LAUNCHES & ENHANCEMENTS, JANUARY 2021-OCTOBER 2024
• TABLE 417 SIMULATIONS PLUS: DEALS, JANUARY 2021-OCTOBER 2024
• TABLE 418 SIMULATIONS PLUS: OTHER DEVELOPMENTS, JANUARY 2021-OCTOBER 2024
• TABLE 419 ADVANCED CHEMISTRY DEVELOPMENT, INC.: COMPANY OVERVIEW
• TABLE 420 ADVANCED CHEMISTRY DEVELOPMENT, INC.: PRODUCTS & SERVICES OFFERED
• TABLE 421 ADVANCED CHEMISTRY DEVELOPMENT, INC.: PRODUCT LAUNCHES & ENHANCEMENTS, JANUARY 2021-OCTOBER 2024
• TABLE 422 ADVANCED CHEMISTRY DEVELOPMENT, INC.: DEALS, JANUARY 2021-OCTOBER 2024
• TABLE 423 CHEMICAL COMPUTING GROUP ULC: COMPANY OVERVIEW
• TABLE 424 CHEMICAL COMPUTING GROUP ULC: PRODUCTS & SERVICES OFFERED
• TABLE 425 CHEMICAL COMPUTING GROUP ULC: DEALS, JANUARY 2021-OCTOBER 2024
• TABLE 426 ROSA & CO. LLC: COMPANY OVERVIEW
• TABLE 427 ROSA & CO. LLC: PRODUCTS & SERVICES OFFERED
• TABLE 428 GENEDATA AG (A DANAHER COMPANY): COMPANY OVERVIEW
• TABLE 429 GENEDATA AG (A DANAHER COMPANY): PRODUCTS & SERVICES OFFERED
• TABLE 430 GENEDATA AG (A DANAHER COMPANY): PRODUCT LAUNCHES & ENHANCEMENTS, JANUARY 2021-OCTOBER 2024
• TABLE 431 GENEDATA AG (A DANAHER COMPANY): DEALS, JANUARY 2021-OCTOBER 2024
• TABLE 432 PHYSIOMICS PLC: COMPANY OVERVIEW
• TABLE 433 PHYSIOMICS PLC: PRODUCTS & SERVICES OFFERED
• TABLE 434 PHYSIOMICS PLC: DEALS, JANUARY 2021-OCTOBER 2024
• TABLE 435 IN SILICO BIOSCIENCES: COMPANY OVERVIEW
• TABLE 436 IN SILICO BIOSCIENCES: PRODUCTS & SERVICES OFFERED
• TABLE 437 ALLUCENT: COMPANY OVERVIEW
• TABLE 438 ALLUCENT: PRODUCTS & SERVICES OFFERED
• TABLE 439 ALLUCENT: DEALS, JANUARY 2021-OCTOBER 2024
• TABLE 440 ALLUCENT: EXPANSIONS, JANUARY 2021-OCTOBER 2024
• TABLE 441 OPENEYE, CADENCE MOLECULAR SCIENCES: COMPANY OVERVIEW
• TABLE 442 OPENEYE, CADENCE MOLECULAR SCIENCES: PRODUCTS & SERVICES OFFERED
• TABLE 443 OPENEYE, CADENCE MOLECULAR SCIENCES: PRODUCT ENHANCEMENTS, JANUARY 2021-OCTOBER 2024
• TABLE 444 OPENEYE, CADENCE MOLECULAR SCIENCES: DEALS, JANUARY 2021-OCTOBER 2024
• TABLE 445 OPENEYE, CADENCE MOLECULAR SCIENCES: EXPANSIONS, JANUARY 2021-OCTOBER 2024
• TABLE 446 CELLWORKS GROUP, INC.: COMPANY OVERVIEW
• TABLE 447 CELLWORKS GROUP, INC.: PRODUCTS & SERVICES OFFERED
• TABLE 448 CELLWORKS GROUP, INC.: EXPANSIONS, JANUARY 2021-OCTOBER 2024
• TABLE 449 VERISIM LIFE: COMPANY OVERVIEW
• TABLE 450 VERISIM LIFE: PRODUCTS & SERVICES OFFERED
• TABLE 451 VERISIM LIFE: DEALS, JANUARY 2021-OCTOBER 2024
• TABLE 452 VERISIM LIFE: OTHER DEVELOPMENTS, JANUARY 2021-OCTOBER 2024
• TABLE 453 NETABOLICS: COMPANY OVERVIEW
• TABLE 454 NETABOLICS: PRODUCTS & SERVICES OFFERED
• TABLE 455 CHARNWOOD DISCOVERY: COMPANY OVERVIEW
• TABLE 456 CHARNWOOD DISCOVERY: PRODUCTS & SERVICES OFFERED
• TABLE 457 CHARNWOOD DISCOVERY: DEALS, JANUARY 2021-OCTOBER 2024
• TABLE 458 THE MATHWORKS, INC.: COMPANY OVERVIEW
• TABLE 459 THE MATHWORKS, INC.: PRODUCTS & SERVICES OFFERED
• TABLE 460 THE MATHWORKS, INC.: PRODUCT ENHANCEMENTS, JANUARY 2021-OCTOBER 2024
• TABLE 461 ANSYS, INC.: COMPANY OVERVIEW
• TABLE 462 ANSYS, INC.: PRODUCTS & SERVICES OFFERED

List of Figures

• FIGURE 1 BIOSIMULATION MARKET SEGMENTATION & REGIONAL SCOPE
• FIGURE 2 RESEARCH DESIGN
• FIGURE 3 PRIMARY SOURCES
• FIGURE 4 BREAKDOWN OF PRIMARY INTERVIEWS (DEMAND SIDE): BY COMPANY TYPE, DESIGNATION, AND REGION
• FIGURE 5 MARKET SIZE ESTIMATION: REVENUE SHARE ANALYSIS
• FIGURE 6 TOP-DOWN APPROACH
• FIGURE 7 CAGR PROJECTIONS, 2024-2029
• FIGURE 8 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS
• FIGURE 9 DATA TRIANGULATION
• FIGURE 10 BIOSIMULATION MARKET, BY OFFERING, 2024 VS. 2029 (USD MILLION)
• FIGURE 11 BIOSIMULATION MARKET, BY APPLICATION, 2024 VS. 2029 (USD MILLION)
• FIGURE 12 BIOSIMULATION MARKET, BY THERAPEUTIC AREA, 2024 VS. 2029 (USD MILLION)
• FIGURE 13 BIOSIMULATION MARKET, BY REVENUE MODEL, 2024 VS. 2029 (USD MILLION)
• FIGURE 14 BIOSIMULATION MARKET, BY DEPLOYMENT MODEL, 2024 VS. 2029 (USD MILLION)
• FIGURE 15 BIOSIMULATION MARKET, BY END USER, 2024 VS. 2029 (USD MILLION)
• FIGURE 16 GEOGRAPHIC SNAPSHOT OF BIOSIMULATION MARKET
• FIGURE 17 INCREASING R&D EXPENDITURE ON DRUG DISCOVERY & DEVELOPMENT BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES TO DRIVE MARKET
• FIGURE 18 CHINA DOMINATED MARKET IN ASIA PACIFIC IN 2023
• FIGURE 19 INDIA TO REGISTER HIGHEST GROWTH RATE DURING FORECAST PERIOD
• FIGURE 20 NORTH AMERICA TO DOMINATE BIOSIMULATION MARKET DURING FORECAST PERIOD
• FIGURE 21 EMERGING ECONOMIES TO REGISTER HIGHER GROWTH RATES DURING FORECAST PERIOD
• FIGURE 22 BIOSIMULATION MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
• FIGURE 23 BIOSIMULATION MARKET: ECOSYSTEM ANALYSIS
• FIGURE 24 BIOSIMULATION MARKET: VALUE CHAIN ANALYSIS
• FIGURE 25 BIOSIMULATION MARKET: PORTER'S FIVE FORCES ANALYSIS
• FIGURE 26 PATENT PUBLICATION TRENDS IN BIOSIMULATION MARKET, 2015-2024
• FIGURE 27 BIOSIMULATION MARKET: PATENT ANALYSIS, JANUARY 2015-SEPTEMBER 2024
• FIGURE 28 INDICATIVE PRICING ANALYSIS FOR BIOSIMULATION SOFTWARE
• FIGURE 29 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF TOP 3 END USERS
• FIGURE 30 KEY BUYING CRITERIA FOR TOP 3 END USERS
• FIGURE 31 TRENDS & DISRUPTIONS IMPACTING CUSTOMERS' BUSINESSES
• FIGURE 32 BIOSIMULATION MARKET: INVESTMENT & FUNDING SCENARIO
• FIGURE 33 MARKET POTENTIAL OF AI/GENERATIVE AI ON BIOSIMULATION
• FIGURE 34 IMPACT OF AI/GEN AI ON INTERCONNECTED AND ADJACENT ECOSYSTEMS
• FIGURE 35 NORTH AMERICA: BIOSIMULATION MARKET SNAPSHOT
• FIGURE 36 ASIA PACIFIC: BIOSIMULATION MARKET SNAPSHOT
• FIGURE 37 REVENUE ANALYSIS OF KEY PLAYERS IN BIOSIMULATION MARKET, 2019-2023 (USD BILLION)
• FIGURE 38 BIOSIMULATION MARKET: MARKET SHARE ANALYSIS (2023)
• FIGURE 39 RANKING OF KEY PLAYERS IN BIOSIMULATION MARKET, 2023
• FIGURE 40 BIOSIMULATION MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2023
• FIGURE 41 BIOSIMULATION MARKET: COMPANY FOOTPRINT
• FIGURE 42 BIOSIMULATION MARKET: COMPANY EVALUATION MATRIX (START-UPS/SMES), 2023
• FIGURE 43 EV/EBITDA OF KEY VENDORS
• FIGURE 44 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF BIOSIMULATION VENDORS
• FIGURE 45 BIOSIMULATION MARKET: BRAND/PRODUCT COMPARATIVE ANALYSIS
• FIGURE 46 CERTARA, USA: COMPANY SNAPSHOT (2023)
• FIGURE 47 DASSAULT SYSTEMES: COMPANY SNAPSHOT (2023)
• FIGURE 48 SCHRODINGER, INC.: COMPANY SNAPSHOT (2023)
• FIGURE 49 SIMULATIONS PLUS: COMPANY SNAPSHOT (2023)
• FIGURE 50 GENEDATA AG (A DANAHER COMPANY): COMPANY SNAPSHOT (2023)
• FIGURE 51 PHYSIOMICS PLC: COMPANY SNAPSHOT (2023)
• FIGURE 52 OPENEYE, CADENCE MOLECULAR SCIENCES: COMPANY SNAPSHOT (2023)
• FIGURE 53 ANSYS, INC.: COMPANY SNAPSHOT (2023)